
XTLB Valuation
X T L Biopharmaceuticals Ltd
- Overview
- Forecast
- Valuation
- Earnings
XTLB Relative Valuation
XTLB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XTLB is overvalued; if below, it's undervalued.
Historical Valuation
X T L Biopharmaceuticals Ltd (XTLB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.05 is considered Undervalued compared with the five-year average of 9.91. The fair price of X T L Biopharmaceuticals Ltd (XTLB) is between 68.64 to 72.37 according to relative valuation methord. Compared to the current price of 1.75 USD , X T L Biopharmaceuticals Ltd is Undervalued By 97.45%.
Relative Value
Fair Zone
68.64-72.37
Current Price:1.75
97.45%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
291.11
P/B
Median3y
277.33
Median5y
318.11
-9.90
FCF Yield
Median3y
-3.80
Median5y
-3.30
Competitors Valuation Multiple
The average P/S ratio for XTLB's competitors is 8.72, providing a benchmark for relative valuation. X T L Biopharmaceuticals Ltd Corp (XTLB) exhibits a P/S ratio of 0.05, which is -99.41% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch

MXL
Maxlinear Inc
16.330
USD
-5.33%

CRTO
Criteo SA
23.085
USD
-0.45%

OFG
OFG Bancorp
43.330
USD
+0.98%

INTR
Inter & Co Inc
6.635
USD
-1.41%

UFPT
UFP Technologies Inc
235.600
USD
-0.21%

OSW
Onespaworld Holdings Ltd
22.170
USD
+0.23%

EVTC
Evertec Inc
33.350
USD
+0.72%

BKV
BKV Corp
20.050
USD
-0.89%

CLOV
Clover Health Investments Corp
3.037
USD
-1.24%

BTE
Baytex Energy Corp
2.085
USD
-2.57%
FAQ

Is X T L Biopharmaceuticals Ltd (XTLB) currently overvalued or undervalued?
X T L Biopharmaceuticals Ltd (XTLB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.05 is considered Undervalued compared with the five-year average of 9.91. The fair price of X T L Biopharmaceuticals Ltd (XTLB) is between 68.64 to 72.37 according to relative valuation methord. Compared to the current price of 1.75 USD , X T L Biopharmaceuticals Ltd is Undervalued By 97.45% .

What is X T L Biopharmaceuticals Ltd (XTLB) fair value?

How does XTLB's valuation metrics compare to the industry average?

What is the current P/B ratio for X T L Biopharmaceuticals Ltd (XTLB) as of Jul 25 2025?

What is the current FCF Yield for X T L Biopharmaceuticals Ltd (XTLB) as of Jul 25 2025?

What is the current Forward P/E ratio for X T L Biopharmaceuticals Ltd (XTLB) as of Jul 25 2025?
